Daan M van Velzen1,2, Alessia Paldino1,3,4, Maartje Klaver1, Nienke M Nota1, Justine Defreyne5,6, G Kees Hovingh7, Abel Thijs1, Suat Simsek1,2, Guy T'Sjoen5,6, Martin den Heijer1. 1. Division of Endocrinology, Department of Internal Medicine, Amsterdam University Medical Center, De Boelelaan, HV Amsterdam, Netherlands. 2. Department of Endocrinology, Northwest Clinics, Wilhelminalaan, JD Alkmaar, Netherlands. 3. Cardiothoracic Department, Azienda Sanitaria Universitaria Integrata, Via Giovanni Sai, Trieste, Italy. 4. University of Trieste, Trieste, Italy. 5. Department of Endocrinology, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium. 6. Center for Sexology and Gender, Ghent University Hospital, Corneel Heymanslaan, Ghent, Belgium. 7. Department of Vascular Medicine, Amsterdam University Medical Center, Meibergdreef DD, Amsterdam, Netherlands.
Abstract
CONTEXT: The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. OBJECTIVE: The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. DESIGN AND METHODS: In this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. RESULTS: Mean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein-cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein-cholesterol levels decreased (HDL-C; 10.8%; 95% CI, -14.0 to -7.6). In transwomen, HT slightly decreased BP (systolic BP, -2.6%, 95% CI, -4.2 to -1.0; diastolic BP, -2.2%, 95% CI, -4.0 to -0.4) and decreased levels of TC (-9.7%; 95% CI, -11.3 to -8.1), LDL-C (-6.0%; 95% CI, -8.6 to 3.6), HDL-C (-9.3%; 95% CI, -11.4 to -7.3), and triglycerides (-10.2%; 95% CI, -14.5 to -5.9). CONCLUSION: Unfavorable changes in lipid profile were observed in transmen; a favorable effect was noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes.
CONTEXT: The impact of gender-affirming hormone therapy (HT) on cardiometabolic parameters is largely unknown. OBJECTIVE: The effects of 1 year of treatment with oral or transdermal administration of estrogen (plus cyproterone) and transdermal or IM application of testosterone on serum lipid levels and blood pressure (BP) were assessed in transgender persons. DESIGN AND METHODS: In this prospective, observational substudy of the European Network for the Investigation of Gender Incongruence, measurements were performed before and after 12 months of HT in 242 transwomen and 188 transmen from 2010 to 2017. RESULTS: Mean values are reported. In transmen, HT increased diastolic BP (2.5%; 95% CI, 0.6 to 4.4) and levels of total cholesterol (TC; 4.1%; 95% CI, 1.5 to 6.6), low-density lipoprotein-cholesterol (LDL-C; 13.0%; 95% CI, 9.2 to 16.8), and triglycerides (36.9%; 95% CI, 29.8 to 44.1); high-density lipoprotein-cholesterol levels decreased (HDL-C; 10.8%; 95% CI, -14.0 to -7.6). In transwomen, HT slightly decreased BP (systolic BP, -2.6%, 95% CI, -4.2 to -1.0; diastolic BP, -2.2%, 95% CI, -4.0 to -0.4) and decreased levels of TC (-9.7%; 95% CI, -11.3 to -8.1), LDL-C (-6.0%; 95% CI, -8.6 to 3.6), HDL-C (-9.3%; 95% CI, -11.4 to -7.3), and triglycerides (-10.2%; 95% CI, -14.5 to -5.9). CONCLUSION: Unfavorable changes in lipid profile were observed in transmen; a favorable effect was noted in transwomen. HT effects on BP were negligible. Long-term studies are warranted to assess whether and to what extent HT in trans individuals results in a differential effect on cardiovascular disease outcomes.
Authors: A D Fisher; G Senofonte; C Cocchetti; G Guercio; V Lingiardi; M C Meriggiola; M Mosconi; G Motta; J Ristori; A M Speranza; M Pierdominici; M Maggi; G Corona; F Lombardo Journal: J Endocrinol Invest Date: 2021-10-22 Impact factor: 4.256
Authors: Madeline K Mahowald; Arvind K Maheshwari; Kyla M Lara-Breitinger; Fadi W Adel; Patricia A Pellikka; Caroline J Davidge-Pitts; Todd B Nippoldt; Birgit Kantor; Rekha Mankad Journal: Am J Prev Cardiol Date: 2021-07-10
Authors: Francisco Javier Martinez-Martin; Agnieszka Kuzior; Alba Hernandez-Lazaro; Ricardo Jose de Leon-Durango; Carlos Rios-Gomez; Borja Santana-Ojeda; Jennifer Maria Perez-Rivero; Paula Maria Fernandez-Trujillo-Comenge; Paula Gonzalez-Diaz; Claudia Arnas-Leon; Carmen Acosta-Calero; Esperanza Perdomo-Herrera; Alba Lucia Tocino-Hernandez; Maria Del Sol Sanchez-Bacaicoa; Maria Del Pino Perez-Garcia Journal: Hypertens Res Date: 2022-10-14 Impact factor: 5.528
Authors: Carl G Streed; Lauren B Beach; Billy A Caceres; Nadia L Dowshen; Kerrie L Moreau; Monica Mukherjee; Tonia Poteat; Asa Radix; Sari L Reisner; Vineeta Singh Journal: Circulation Date: 2021-07-08 Impact factor: 39.918
Authors: Paul J Connelly; E Marie Freel; Colin Perry; John Ewan; Rhian M Touyz; Gemma Currie; Christian Delles Journal: Hypertension Date: 2019-10-28 Impact factor: 10.190